Clinical trials: Stage II Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT01279473
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed/Refractory Chronic Lymphocytic Leukemia
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
An open-label, multicenter, phase Ib/II clinical trial was conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of GNC-035 quad-specific antibody injection in patients with…
- Trial name
- NCT05944978
- Testing
- GNC-035
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Leukemia, Lymphoma
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Biological therapies such as denileukin diftitox may be able to deliver cancer-killing substances directly to non-Hodgkin's lymphoma cells.
- Trial name
- NCT00026429
- Testing
- denileukin diftitox
- Where
- 6 sites in United States
- Sponsor
- Pharmatech Oncology
Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
This is an open-label, two-part study to assess the safety, tolerability, pharmacokinetics and clinical efficacy of acalabrutinib in Chinese adult subjects with R/R MCL, CLL and other B-cell malignancies.
- Conditions
- Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT03932331
- Testing
- Acalabrutinib
- Where
- 23 sites in China
- Volunteers
- 105 people
- Sponsor
- AstraZeneca
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
The purpose of this study is to determine whether ublituximab in combination with lenalidomide (Revlimid®) is safe and effective in patients with B-Cell Lymphoid Malignancies who have relapsed or are refractory after CD20…
- Conditions
- Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas
- Trial name
- NCT01744912
- Testing
- Ublituximab, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- TG Therapeutics, Inc.
Leukaemia, Lymphocytic, Chronic
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia
Ofatumumab is an IgG1κ fully human monoclonal antibody (mAb) that specifically recognizes an epitope on the human differentiation antigen CD20 molecule.
- Trial name
- NCT01077622
- Testing
- ofatumumab 100 mg, 1000 mg / vial
- Where
- 7 sites in Japan, South Korea
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Lymphocytic Leukemia, Chronic
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with refractory chronic lymphocytic leukemia.
- Trial name
- NCT00431873
- Testing
- MGCD0103
- Where
- 13 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Mirati Therapeutics Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.
- Trial name
- NCT05147467
- Testing
- APG2575
- Where
- 11 sites in China
- Volunteers
- 75 people
- Sponsor
- Ascentage Pharma Group Inc.
Lymphocytic Leukemia, Chronic
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
This single arm, open-label study will assess the safety and efficacy of low dose fludarabine and cyclophosphamide in combination with standard dose MabThera/Rituxan (rituximab) as primary therapy in elderly patients (>/= 65…
- Trial name
- NCT01263704
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 12 sites in Israel
- Volunteers
- 42 people
- Sponsor
- Hoffmann-La Roche
Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
The purpose of this research study is to determine the safety and tolerability of TL-895. There are 2 parts of this study. Part 1 tested increasing doses of TL-895 to identify the recommended safe dose for participants with…
- Conditions
- Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT02825836
- Testing
- TL-895, Navtemadlin
- Where
- 17 sites in United States, Hungary and 5 more
- Volunteers
- 130 people
- Sponsor
- Telios Pharma, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323).
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
- Trial name
- NCT03960840
- Testing
- Rapcabtagene autoleucel single agent, Ibrutinib
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 218 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphocytic, Chronic, B-Cell
DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia
Phase 2 study to assess the efficacy of INVAC-1, a DNA plasmid encoding a modified human telomerase reverse transcriptas (hTERT) protein, at a dose of 800 µg for 6 cycles 4 weeks apart on Minimal Residual Disease (MRD)…
- Trial name
- NCT03265717
- Testing
- INVAC-1
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Invectys
AML, Advanced MDS
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
The purpose of Phase I of this study is to test the safety and tolerability of the investigational drug, OTS167, and that of Phase II of this study is to confirm the potential response benefit of OTS167.
- Conditions
- AML, Advanced MDS, ALL, Advanced CML
- Trial name
- NCT02795520
- Testing
- OTS167IV
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- OncoTherapy Science, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.
- Trial name
- NCT04494503
- Testing
- APG-2575, Rituximab, Ibrutinib
- Where
- 18 sites in China
- Volunteers
- 123 people
- Sponsor
- Ascentage Pharma Group Inc.
Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL)
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and combination therapy may provide improved clinical benefit.
- Conditions
- Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström Macroglobulinemia (WM)
- Trial name
- NCT07609862
- Testing
- Lacutoclax+Rocbrutinib
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
This is a two-cohort, multicenter, open-label study of tafasitamab (MOR208) combined with idelalisib or venetoclax in adult patients with R/R CLL or R/R SLL pretreated with a BTK inhibitor (e.g., ibrutinib) as single agent or as…
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- COSMOS (NCT02639910)
- Testing
- Tafasitamab, Idelalisib, Venetoclax
- Where
- 17 sites in United States, Austria and 4 more
- Volunteers
- 24 people
- Sponsor
- MorphoSys AG
Chronic Lymphocytic Leukemia
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
This is an open-label, multicenter, Phase I/II study of the safety of escalating doses of single-agent PRO131921 in patients with chronic lymphocytic leukemia (CLL) who have relapsed after or were refractory to treatment with a…
- Trial name
- NCT00496132
- Testing
- PRO131921
- Volunteers
- 16 people
- Sponsor
- Genentech, Inc.
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use.
- Trial name
- Atalanta-1 (NCT06561425)
- Testing
- GLPG5101
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 130 people
- Sponsor
- Lakefront Biotherapeutics NV
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
The primary objectives are to evaluate the safety and tolerability of hLL1-DOX, and to determine the maximum tolerated dose (MTD) regimen (in terms of a dose and its associated dosing schedule).
- Trial name
- NCT01585688
- Testing
- hLL1-DOX (IMMU-115)
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Gilead Sciences
NHL, Lymphoma, Non-Hodgkin
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
The purpose of this study is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in NHL or CLL patients and to confirm the safety and efficacy of veltuzumab that was previously established when…
- Conditions
- NHL, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Follicular
- Trial name
- NCT00546793
- Testing
- veltuzumab
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences